The CORDIALLY real-world study was conducted to improve insight into the treatment patterns of patients with T2D initiating modern antidiabetic medications (SGLT2i, GLP-1 RA, and DPP4i) in five CEE countries (Bulgaria, Czech Republic, Hungary, Poland, and Russia), based on a snapshot taken in autumn 2018. Here, GLP1R is linked to type 2 diabetes mellitus.